Peter Mueller, PhD
President of R&D and Chief Scientific Officer
Prior to his time at Pronutria Biosciences, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals.
provided strategic oversight for Vertex's worldwide drug discovery and development programs.
was responsible for build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain as well as Clinical and Non-Clinical Development, Regulatory and Medical Affairs and Patient Safety.
Key areas of Vertex' R&D
have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases.
leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submissions for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia.
Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) and its European counterpart the Galenus Preis (Kalydeco).
The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration.
In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD,Cancer, TB).
Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997.
played a key role in the development of Spiriva, Combivent and Atrovent.
also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis.
time with Boehringer Ingelheim
, starting there in 1984, Dr. Mueller
oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a PhD in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry.
completed fellowships in Quantum Pharmacology at Oxford University
and in Biophysics at Rochester University
Special Fields of studies are Synthetic Organic Chemistry, Computational Chemistry (Cheminformatics and Bioinformatics), RNA-Biophysics, Atherosclerosis Research, IMID (Immune Mediated Inflammatory Diseases), Neurodegenerative Diseases, Infection, Oncology, Gene/ Epigenetic Technology and Management Strategies.
He is a (Board) member of various scientific and political societies, such as the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (UK); US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, IRI, RNA-Society, ASAP, AAAS (USA), Harvard Accelerator Fund, and SAB for Keystone Conferences and serves also on the Board of Inhibikase.
Before he left Connecticut to join Vertex, Dr. Mueller was a member of Governor Roland's Council on Economic Competitiveness and Technology for the State of Connecticut (USA).